SHP2 activity is required for survival of receptor tyrosine kinases (RTK)-driven cancer cells [7] and is involved in intrinsic and acquired resistance to targeted cancer drugs [8], [9], [10], [11], [12], [13], [14], [15]. This evidence concerns the gene NTRK1 and cancer.